Caffeine and Sodium Citrate Ingestion

• ClinicalTrials.gov Identifier: NCT01591226
• Recruitment Status: Completed
• First Posted: May 3, 2012
• Last Update Posted: November 22, 2016
• Sponsor: Swiss Paraplegic Centre Nottwil
• Information provided by (Responsible Party): Swiss Paraplegic Centre Nottwil

Study Description

Brief Summary:

A positive ergogenic effect of sodium citrate and caffeine ingestion in a short-term, high-intensity exercise task was shown by several studies. These studies were conducted with healthy, able-bodied subjects.

The aim of the study is to investigate whether caffeine or sodium citrate ingestion could enhance performance in spinal cord injured wheelchair athletes. It is a double blind, placebo controlled and randomized study.

Condition or disease	Intervention/treatment	Phase
Dietary Supplements; Heart Rate/Drug Effects; Lactic Acid/Metabolism; Physical Education and Training/Methods; Wheelchairs	Dietary Supplement: Caffeine; Dietary Supplement: Sodium Citrate; Dietary Supplement: Mannitol; Dietary Supplement: Sodium Chloride	Not Applicable

Detailed Description:

The athletes have to complete four 1500m tests on a training roller. Before each treatment they get different supplementations. Once they get sodium citrate and a placebo, once caffeine and a placebo, once sodium citrate and caffeine and for the fourth treatment they get twice a placebo. Two hours after starting with the supplementation they have to complete the 1500m as fast as possible. Time to complete 1500m, blood pH, plasma bicarbonate, sodium concentration, heart rate, oxygen consumption, blood lactate concentration and rate of perceived exertion (RPE) were measured.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 9 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: Triple (Participant, Care Provider, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: Effects of Caffeine and Sodium Citrate Ingestion in 1500m Wheelchair Racing Athletes
• Study Start Date: February 2012
• Actual Primary Completion Date: September 2012
• Actual Study Completion Date: September 2012

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Caffeine; 6mg per kg bodyweight ingested 60min before test	Dietary Supplement: Caffeine; gelatine capsule 6mg/kg bodyweight 60min prior test; Dietary Supplement: Sodium Chloride; sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Placebo Comparator: Placebo; Sodium chloride and mannitol as placebo are ingested by the athlete	Dietary Supplement: Mannitol; gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test; Dietary Supplement: Sodium Chloride; sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Active Comparator: Sodium Citrate; sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test	Dietary Supplement: Sodium Citrate; 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test; Dietary Supplement: Mannitol; gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
Active Comparator: Caffeine and Sodium Citrate; sodium citrate 120-90min prior test capsules:60min prior test	Dietary Supplement: Caffeine; gelatine capsule 6mg/kg bodyweight 60min prior test; Dietary Supplement: Sodium Citrate; 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test

Outcome Measures

Primary Outcome Measures :

1. Time [ Time Frame: 3 weeks ]
   Time to complete 1500m

Secondary Outcome Measures :

1. Heart Rate [ Time Frame: during study phase of 3 week (4 tests) ]
   Heart Rate measured from 2min before the test until 5min after the 1500m-test.
2. Lactate Concentration [ Time Frame: during the 3 weeks study phase ]
   1min before starting the warm up, 15s after the end of the warm up, 15s after completing the test, 2min/4min/6min/8min/10min after the test
3. blood pH, sodium concentration and plasma bicarbonate [ Time Frame: during the 3 weeks of study phase ]
   1min before starting with the ingestion of the fluid, immediately before starting the warm up, just immediately before starting the 1500m test.
4. Oxygen Consumption [ Time Frame: during 3 weeks of study phase ]
   oxygen consumption (VO2(ml/min/kg), VCO2(ml/min), RER (VCO2/VO2)) starting of the measurement is 2min before the start of the 1500m and ends 2min after having completed the 1500m
5. rating of gastrointestinal stress [ Time Frame: during the 3 weeks of study phase ]
   1min before starting to drink the fluid, 2min before starting with the warm up, 2min before the test and 2min after having completed the 1500m
6. Rating of Perceived Exertion (RPE) [ Time Frame: during the 3 weeks of study phase ]
   15s after the end of the warm up, 15s after having completed the 1500m

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• wheelchair athletes
• national team
• category T53 and T54

Exclusion Criteria:

• medicated
• pregnant (for women)
• cardiovascular and respiratory diseases

Contacts and Locations

Locations

Switzerland

Swiss Paraplegic Centre

Nottwil, Lucerne, Switzerland, 6207

Sponsors and Collaborators

Swiss Paraplegic Centre Nottwil

Investigators

• Principal Investigator: Claudio Perret, Dr. sc. nat.; Swiss Paraplegic Centre Nottwil

More Information

• Responsible Party: Swiss Paraplegic Centre Nottwil
• ClinicalTrials.gov Identifier: NCT01591226 History of Changes
• Other Study ID Numbers: 2012-02
• First Posted: May 3, 2012
• Last Update Posted: November 22, 2016
• Last Verified: November 2016

Keywords provided by Swiss Paraplegic Centre Nottwil:

caffeine; sodium citrate; exercise performance; wheelchair athletes; 1500m

Additional relevant MeSH terms:

Mannitol; Caffeine; Citric Acid; Sodium Citrate; Anticoagulants; Calcium Chelating Agents; Chelating Agents; Sequestering Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Stimulants; Physiological Effects of Drugs; Phosphodiesterase Inhibitors; Enzyme Inhibitors; Purinergic P1 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Neurotransmitter Agents; Diuretics, Osmotic; Diuretics; Natriuretic Agents